Literature DB >> 8088064

Detection of stromelysin in synovial fluid and serum from patients with rheumatoid arthritis and osteoarthritis.

S Sasaki1, H Iwata, N Ishiguro, K Obata, T Miura.   

Abstract

Stromelysin levels were measured using a one-step sandwich immunoassay in synovial fluid (SF) obtained from 31 patients with rheumatoid arthritis (RA) (31 samples) and 13 patients with osteoarthritis (OA) (13 samples) and in serum from 81 patients with RA (106 samples), 12 with OA (14 samples), 12 with gouty arthritis (gout) (14 samples), and 8 with osteoporosis (OP) (14 samples) to identify differences in the levels in these diseases as well as correlations with clinical parameters in RA. SF stromelysin levels were significantly higher in RA than in OA, and rose with increasing joint destruction in the former. No significant correlations were found between the SF stromelysin level in RA and various clinical parameters, except for the volume of SF which showed a correlation. Serum levels of stromelysin were highest in RA, gout, OA, and osteoporosis in decreasing order, and in RA were correlated with the Steinbrocker Stage. A significant correlation was also found between the serum stromelysin level and number of swollen joints, and correlations with the Lansbury index, ESR, CRP, WBC and Plt. The stromelysin level in SF was thought to be a useful parameter of local joint involvement and that in serum of the severity of systemic joint inflammation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8088064     DOI: 10.1007/bf02249017

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  13 in total

1.  Cell-mediated degradation of type IV collagen and gelatin films is dependent on the activation of matrix metalloproteinases.

Authors:  S J Atkinson; R V Ward; J J Reynolds; G Murphy
Journal:  Biochem J       Date:  1992-12-01       Impact factor: 3.857

2.  Report of a three-year study on the systemic and articular indexes in rheumatoid arthritis; theoretic and clinical considerations.

Authors:  J LANSBURY
Journal:  Arthritis Rheum       Date:  1958-12

3.  Therapeutic criteria in rheumatoid arthritis.

Authors:  O STEINBROCKER; C H TRAEGER; R C BATTERMAN
Journal:  J Am Med Assoc       Date:  1949-06-25

4.  Degradation of type IX collagen by matrix metalloproteinase 3 (stromelysin) from human rheumatoid synovial cells.

Authors:  Y Okada; H Konomi; T Yada; K Kimata; H Nagase
Journal:  FEBS Lett       Date:  1989-02-27       Impact factor: 4.124

5.  The interleukin-1 receptor in normal and osteoarthritic human articular chondrocytes. Identification as the type I receptor and analysis of binding kinetics and biologic function.

Authors:  J Martel-Pelletier; R McCollum; J DiBattista; M P Faure; J A Chin; S Fournier; M Sarfati; J P Pelletier
Journal:  Arthritis Rheum       Date:  1992-05

6.  A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 3 (stromelysin-1) using monoclonal antibodies.

Authors:  K Obata; K Iwata; Y Okada; Y Kohrin; E Ohuchi; S Yoshida; M Shinmei; T Hayakawa
Journal:  Clin Chim Acta       Date:  1992-10-15       Impact factor: 3.786

7.  Detection of stromelysin and collagenase in synovial fluid from patients with rheumatoid arthritis and posttraumatic knee injury.

Authors:  L A Walakovits; V L Moore; N Bhardwaj; G S Gallick; M W Lark
Journal:  Arthritis Rheum       Date:  1992-01

8.  Neutral proteases capable of proteoglycan digesting activity in osteoarthritic and normal human articular cartilage.

Authors:  J Martel-Pelletier; J P Pelletier; J M Cloutier; D S Howell; L Ghandur-Mnaymneh; J F Woessner
Journal:  Arthritis Rheum       Date:  1984-03

9.  Cell proliferation-related production of matrix metalloproteinases 1 (tissue collagenase) and 3 (stromelysin) by cultured human rheumatoid synovial fibroblasts.

Authors:  K Hiraoka; Y Sasaguri; S Komiya; A Inoue; M Morimatsu
Journal:  Biochem Int       Date:  1992-09

10.  Effects of interleukin-6 on the metabolism of connective tissue components in rheumatoid synovial fibroblasts.

Authors:  A Ito; Y Itoh; Y Sasaguri; M Morimatsu; Y Mori
Journal:  Arthritis Rheum       Date:  1992-10
View more
  11 in total

1.  Synovial proinflammatory cytokines and their correlation with matrix metalloproteinase-3 expression in Behçet's disease. Does interleukin-1beta play a major role in Behçet's synovitis?

Authors:  Salih Pay; Hakan Erdem; Aysel Pekel; Ismail Simsek; Ugur Musabak; Ali Sengul; Ayhan Dinc
Journal:  Rheumatol Int       Date:  2005-10-05       Impact factor: 2.631

2.  Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment.

Authors:  C Ribbens; M Martin y Porras; N Franchimont; M-J Kaiser; J-M Jaspar; P Damas; F A Houssiau; M G Malaise
Journal:  Ann Rheum Dis       Date:  2002-02       Impact factor: 19.103

3.  Intra-articular injection of hyaluronate and indomethacin in rabbits with antigen-induced arthritis.

Authors:  Yow-Jen Lo; Ming-Thau Sheu; Wen-Chi Tsai; Yun-Ho Lin; Jau-Le Li; Yu-Chih Liang; Chi-Ching Chang; Ming-Shium Hsieh; Chien-Ho Chen
Journal:  Rheumatol Int       Date:  2007-04-14       Impact factor: 2.631

4.  Measurement of inflammatory biomarkers in synovial tissue extracts by enzyme-linked immunosorbent assay.

Authors:  Sanna Rosengren; Gary S Firestein; David L Boyle
Journal:  Clin Diagn Lab Immunol       Date:  2003-11

5.  Increased serum proMMP-3 in inflammatory arthritides: a potential indicator of synovial inflammatory monokine activity.

Authors:  D J Taylor; N T Cheung; P T Dawes
Journal:  Ann Rheum Dis       Date:  1994-11       Impact factor: 19.103

6.  Comparison of efficacy between anti-IL-6 receptor antibody and other biological disease-modifying antirheumatic drugs in the patients with rheumatoid arthritis who have knee joint involvement: the ANSWER cohort, retrospective study.

Authors:  Yuichi Maeda; Toru Hirano; Kosuke Ebina; Ryota Hara; Motomu Hashimoto; Wataru Yamamoto; Kosaku Murakami; Takuya Kotani; Kenichiro Hata; Yonsu Son; Hideki Amuro; Akira Onishi; Sadao Jinno; Masaki Katayama; Atsushi Kumanogoh
Journal:  Rheumatol Int       Date:  2021-04-26       Impact factor: 2.631

7.  Matrix metalloproteinase-3 inhibitor retards treadmill running-induced cartilage degradation in rats.

Authors:  Guo-Xin Ni; Li-Qiong Zhan; Mei-Qin Gao; Lei Lei; Yue-Zhu Zhou; Yan-Xia Pan
Journal:  Arthritis Res Ther       Date:  2011-11-24       Impact factor: 5.156

8.  Serum matrix metalloproteinase-3 as a noninvasive biomarker of histological synovitis for diagnosis of rheumatoid arthritis.

Authors:  Jian-Da Ma; Jing-Jing Zhou; Dong-Hui Zheng; Le-Feng Chen; Ying-Qian Mo; Xiu-ning Wei; Li-Juan Yang; Lie Dai
Journal:  Mediators Inflamm       Date:  2014-07-23       Impact factor: 4.711

9.  Proteoform Analysis of Matrix Metalloproteinase-9/Gelatinase B and Discovery of Its Citrullination in Rheumatoid Arthritis Synovial Fluids.

Authors:  Bernard Grillet; Karen Yu; Estefania Ugarte-Berzal; Rik Janssens; Rafaela Vaz Sousa Pereira; Lise Boon; Erik Martens; Nele Berghmans; Isabelle Ronsse; Ilse Van Aelst; Pierre Fiten; René Conings; Jennifer Vandooren; Patrick Verschueren; Jo Van Damme; Paul Proost; Ghislain Opdenakker
Journal:  Front Immunol       Date:  2021-11-29       Impact factor: 7.561

10.  Serum pro-matrix metalloproteinase-3 as an indicator of disease activity and severity in rheumatoid arthritis: comparison with traditional markers.

Authors:  Aşkin Ateş; Nuran Türkçapar; Umit Olmez; Olcay Tiryaki; Nurşen Düzgün; Emre Uğuz; Murat Duman
Journal:  Rheumatol Int       Date:  2007-04-11       Impact factor: 3.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.